Bayer HealthCare

What Bayer HealthCare does

Bayer HealthCare is the healthcare division of Bayer AG, a German multinational pharmaceutical and life sciences company headquartered in Leverkusen, Germany with 10,000+ employees in the division. The division operates across three segments: Pharmaceuticals (prescription drugs targeting oncology, cardiovascular disease, and radioligand therapy), Consumer Health (over-the-counter supplements including the One A Day brand), and Animal Health (veterinary pharmaceuticals including the Advocate parasiticide). Customers span healthcare providers and hospital systems for prescription products, retail consumers for supplements through pharmacies and supermarkets, and veterinary clinics and pet retailers for animal health products.

The pharmaceutical portfolio centers on oncology assets such as Nubeqa (darolutamide), an oral androgen receptor inhibitor approved for non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and combinations with docetaxel. Bayer supports radioligand therapy clinical development through an EORTC partnership covering the LUMEN-1, RENALUT, and PEACE III trials, the last of which demonstrated adding radium-223 to enzalutamide increased median progression-free survival from 16 to 19 months in prostate cancer patients with bone metastases. Bayer also invests in precision oncology AI research using large language models and multi-agent systems for cancer treatment analysis. Consumer health includes One A Day Men's Pre-Conception Health (subject to NAD review on certain claims), while animal health includes Advocate, a broad-spectrum imidacloprid/moxidectin parasiticide for dogs and cats.

The business model combines B2B prescription drug sales through hospital pharmacy networks globally (with a presence in the USD 22.7 billion global VEGF inhibitor market), B2C retail sales of consumer supplements through mass-market and direct-to-consumer channels, and veterinary channel distribution for animal health in markets including the USD 4.21 billion Europe companion animal segment. Bayer HealthCare is wholly owned by publicly traded Bayer AG (Frankfurt Stock Exchange, ticker BAYZN), and the parent operates additional Crop Science and Consumer Health divisions with 13+ German sites spanning manufacturing production, R&D, and corporate functions. Recent corporate-level moves include a Dynamic Shared Ownership transformation initiative (2026), the creation of a standalone US glyphosate unit named Ruveon (July 2026), and the February 2026 termination of the Ovaprene license with Dare Bioscience.

Name

Bayer HealthCare

Legal name

Bayer AG

Website

https://bayerhealthcare.com

Company type

Public

Founded year

1863

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Bayer HealthCare is the healthcare division of German multinational Bayer AG, developing prescription pharmaceuticals (Nubeqa for prostate cancer, radioligand therapies), consumer health supplements (One A Day), and animal health products (Advocate parasiticide) for global healthcare providers, consumers, and veterinary channels.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Pet Pharmaceuticals & Veterinary Supply Distribution (CRAOAKAD)

Keywords

• Prescription pharmaceuticals
• Oncology therapeutics
• Consumer health supplements
• Veterinary parasiticides
• Medical imaging contrast media

Headquarters

HQ city

Leverkusen

HQ country

Germany

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceuticals: Prescription pharmaceuticals including VEGF inhibitors, oncology drugs, cardiovascular medications, and radioligand therapies sold to healthcare systems, hospitals, and pharmacies globally.
2. Consumer Health: Over-the-counter supplements and consumer health products including One A Day vitamins and men's health supplements sold through retail and direct-to-consumer channels.
3. Animal Health: Veterinary pharmaceuticals and parasiticide products like Advocate for companion animals (dogs and cats) distributed through veterinary clinics and pet retailers.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Bayer HealthCare develops, manufactures, and commercializes prescription pharmaceuticals (notably Nubeqa/darolutamide for prostate cancer and VEGF inhibitors for solid tumors), consumer health dietary supplements (One A Day Men's Pre-Conception Health), veterinary parasiticides (Advocate, combining imidacloprid and moxidectin for dogs and cats), and high-pressure contrast media injectors used in medical imaging. The division serves healthcare providers, hospital systems, retail consumers, and veterinary clinics across global markets with an R&D pipeline focused on oncology, cardiovascular, and radioligand therapy.

Product overview

Bayer HealthCare operates as a division of Bayer AG, offering a portfolio of pharmaceutical and consumer health products. The pharmaceutical portfolio includes oncology treatments such as Nubeqa (darolutamide) for prostate cancer, while the consumer health segment includes dietary supplements like One A Day Men's Pre-Conception Health. Bayer Animal Health, part of the Bayer group, produces veterinary pharmaceuticals including the Advocate parasiticide for companion animals. The portfolio reflects a mix of prescription pharmaceuticals and over-the-counter consumer health products.

Differentiator

Problem solved

Functional benefit

Brands

• One A Day: Vitamin and supplement brand for men's and women's health including Pre-Conception Health supplements
• Advocate
• Nubeqa

Products and services

• Nubeqa (Darolutamide) Oral androgen receptor inhibitor indicated for treatment of adult patients with non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and metastatic castration-sensitive prostate cancer in combination with docetaxel.
• One A Day Men's Pre-Conception Health Dietary supplement marketed for men's pre-conception health and fertility support under the One A Day consumer health brand.
• Advocate (Bayer Animal Health) Broad-spectrum endectocide parasiticide combining imidacloprid and moxidectin in a topical formulation for dogs and cats, offering prevention and treatment for fleas, intestinal nematodes, ear mites, and heartworm.

Quantifiable outcome

• PEACE III trial: Adding radium-223 to enzalutamide increased median progression-free survival from 16 to 19 months in prostate cancer patients with bone metastases

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Dare BioscienceminorOEM/ Whitelabel/ Licensing Partner · 1 February 2026Bayer HealthCare held license rights to Dare Bioscience's hormone-free contraceptive Ovaprene. Bayer terminated the license agreement effective February 2026, with Dare Bioscience regaining full rights to the product.
• EORTC (European Organisation for Research and Treatment of Cancer)coreStrategic or Co-development Partner · 8 October 2025Bayer HealthCare Pharmaceuticals Inc. supports EORTC's radioligand therapy clinical trials including LUMEN-1, RENALUT, and PEACE III. The collaboration advances targeted radiopharmaceutical treatments for cancer including meningioma, renal cancer, and prostate cancer with bone metastases.
• Amgen, AstraZeneca, RochecoreStrategic or Co-development Partner · 1 January 2024Bayer is among the multinational pharmaceutical companies with approved collaborations for clinical trials in China under the 'managed openness' regulatory framework. China's approach permits cross-border collaboration in lower-risk areas such as oncology and pharmaceutical clinical trials.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Boehringer Ingelheim: Direct peer across both human pharmaceuticals and animal health (Boehringer Ingelheim Animal Health), making it the most directly comparable to Bayer HealthCare's diversified healthcare structure with overlapping therapeutic areas and animal health portfolio.
• Zoetis: Direct peer and global leader in animal health pharmaceuticals, operating with similar veterinary pharmaceuticals R&D and commercialization model as Bayer Animal Health, competing head-to-head with Advocate and other parasiticide franchises.
• Elanco Animal Health: Direct peer in animal health, specifically named as a Bayer Animal Health competitor in Europe companion animal healthcare. Overlapping parasiticide and therapeutic portfolios make it a directly comparable operator in Bayer's veterinary segment.
• Amgen: Direct peer named as a Bayer collaboration partner in China's clinical trial framework, with overlapping biologic oncology and biosimilar portfolios directly comparable to Bayer's branded innovator pharmaceutical business.

Broad incumbents

• Roche: Broad incumbent peer with deeply overlapping oncology franchise and named as a peer in Bayer's regulatory/collaboration landscape. Comparable in oncology pipeline focus and radiopharmaceutical/diagnostic adjacency.
• Novartis: Broad incumbent pharma peer with overlapping oncology, cardiovascular, and radioligand therapy (Lutathera, Pluvicto) investments directly comparable to Bayer's Nubeqa and radium-223 franchises.
• Pfizer: Broad pharma peer with overlapping oncology, cardiovascular, and consumer health offerings, comparable in scale and therapeutic area breadth to Bayer HealthCare's prescription pharmaceutical division.
• AstraZeneca: Broad incumbent pharma peer named as a Bayer collaboration partner in China's clinical trial framework. Comparable in oncology pipeline scale and cardiovascular therapeutic overlap.
• Sanofi: Broad incumbent comparable to Bayer HealthCare's diversified pharma plus consumer health model, with directly overlapping OTC consumer health portfolio and specialty pharma franchises.
• Merck & Co. Broad incumbent pharma peer named in Bayer's competitive landscape for Europe companion animal healthcare. Operates in oncology, vaccines, and animal health (Merck Animal Health), making it a comparable diversified healthcare conglomerate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bayer-healthcare-pharmaceuticals-llc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bayer HealthCare